HHS Lets Pharmacies Compound Peptides as FDA Writes Official Rule

In the meantime, FDA will decide through rulemaking whether the peptides officially belong on the 503A Bulks List in the future, keeping open a door of uncertainty heading into 2027 as demand for these peptides grows.^1,2

“Based on the Pharmacy Compounding Advisory Committee (PCAC) meeting and data regarding utilization of peptides, HHS believes that there is significant interest in the use of these peptides in compounding,” writes HHS representatives.¹ “HHS also believes based on the PCAC meeting that public comments may provide additional evidence that FDA can consider in rulemaking to address some or all of the substances. Therefore, to expand and improve patient access while FDA reviews these substances, HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a bulk drug substance in Appendix A.”

As pharmacies across the nation, alongside health care leaders and decision makers, grapple with these new exceptions in the peptide space, it’s important to stay up to date with key policy and legislative announcements in order for pharmacies to stay compliant and patients to stay safe in their prescription drug regimens.

READ MORE: Pharmacists Must Guide Peptide Talks Pending FDA Action | NCPA 2026

HHS Peptide Compounding Policy and the New Conditions for Patient Access

The policy document outlining enforcement discretion for 6 peptides could substantially change how compounding pharmacies, health care providers, and telemedicine companies approach peptide therapies. The document describes a conditional pathway for patient access to the 6 aforementioned peptides while FDA develops the Section 503A bulk drug substances list through rulemaking.

The opportunity is significant, but the conditions warrant careful attention. The text ties enforcement discretion with specific chemical identities, administration routes, manufacturing standards, testing, and reporting. This analysis addresses the document reviewed and how stakeholders should confirm official issuance and the operative version before relying on its provisions.

What Would Change Under the HHS Peptide Policy

Section 503A of the Federal Food, Drug, and Cosmetic (FD&C) Act provides qualifying compounded drugs with exemptions from certain federal requirements, including premarket approval. Its bulk-substance requirements generally look to an applicable United States Pharmacopeia or National Formulary monograph, a component of an FDA-approved drug where no monograph exists, or inclusion on the 503A bulks list when neither applies.

The HHS document addresses specified peptides that do not satisfy those pathways. It states that HHS does not intend to take enforcement action against qualifying state-licensed pharmacies, federal facilities, and licensed physicians when all stated conditions are met, pending a final rule including or excluding the substance. It does not, however, extend this policy to Section 503B outsourcing facilities.

HHS explains that supervised compounding could provide an alternative to research-use-only peptides entering the market without adequate safeguards. Appendix B cites updated characterization, utilization information, and PCAC's recommendations, while acknowledging that FDA's Center for Drug Evaluation and Research (CDER) recommended against listing these substances. These differing assessments matter when explaining the policy to patients.

Enforcement discretion would not constitute FDA approval, amend Section 503A, or establish that a particular treatment is safe and effective. HHS also reserves the ability to revisit the policy, including in response to safety signals or product-quality concerns. Businesses, therefore, should avoid treating interim access as a permanent regulatory entitlement.

Which Peptides and Administration Routes Are Covered

Appendix A names 6 peptides, but Appendix B supplies the controlling identities and route limitations. For BPC-157, the specified substance is BPC-157 acetate for subcutaneous, intramuscular, oral, and topical dosage forms. The document identifies KPV acetate for topical and oral use and Semax free base for intranasal use.

TB-500 acetate and MOTS-c acetate are addressed for subcutaneous or intramuscular injections. Epitalon acetate is similarly addressed for subcutaneous or intramuscular injections, with the additional limitation that it be dispensed in intermittent courses. A pharmacy cannot assume that a familiar peptide name covers every salt, derivative, formulation, or route offered by suppliers.

The distinction has immediate commercial consequences. Injectable KPV, injectable Semax, and intravenous administration are not within the routes described in Appendix B. Other peptides, including CJC-1295, ipamorelin, AOD-9604, and emideltide, also are absent from Appendix A and receive no protection from this particular policy.

READ MORE: Pharmacy Law Lowdown: FDA’s Evaluation of Peptides

What Pharmacies Must Verify About Peptide Suppliers

The original active pharmaceutical ingredient (API) manufacturer must be registered with FDA under Section 510, comply with current good manufacturing practice and other applicable requirements, and have its physical manufacturing location identified on the certificate of analysis. Registration of a distributor or re-packer does not substitute for registration of the original manufacturer. If an FDA-registered intermediary supplies the substance, the policy also calls for that intermediary to document validation of the manufacturer and its certificate.

Appendix B makes clear that a certificate reporting a purity percentage alone would be insufficient. Its testing framework addresses identity, potency, peptide-related impurities, residual solvents, elemental impurities, and microbiological quality, including bacterial endotoxins for injectable preparations. Additional characterization requirements depend on the substance. Where orthogonal methods are specified, at least 2 independent analytical procedures using different physicochemical principles are contemplated.

Pharmacies should obtain the underlying documentation needed to evaluate each supplied lot and its intended dosage form. Appendix B also identifies manufacturing and laboratory information, batch and dating details, storage conditions, and designation for human drug compounding. FDA registration should never be presented to patients as FDA approval of the ingredient or finished preparation.

Why Formulations and Delivery Systems Require Separate Review

The document limits covered preparations for a single API listed in Appendix A. A BPC-157 and TB-500 combination would therefore fall outside the described policy, even though each peptide appears individually. Pharmacies and telemedicine companies offering peptide blends should review their product menus before assuming those formulations qualify.

Oral preparations present another hurdle. For an oral peptide formulation, the compounder is expected to maintain documentation confirming adequate oral bioavailability in humans for the specific formulation provided to the patient. General information about the peptide or evidence involving a different formulation would not establish that condition.

The device provision also deserves attention before selecting packaging. It identifies an FDA 510(k)-cleared syringe as the only delivery device that may be co-packaged with or contain the compounded drug. Its interaction with intranasal Semax warrants clarification, and businesses should not assume that pen injectors or other delivery systems qualify.

Reporting and Labeling Become Operational Requirements

The policy calls for reporting compounded products, serious adverse events, and product-quality issues to FDA and the states where the products are compounded and sent, if different. Product information includes the API and strength per unit, original manufacturer and unique facility identifier, dosage form, and administration route. Compounders would report serious adverse events and quality issues through FDA's MedWatch program.

READ MORE: Q&A: Understanding the Pharmaceutical Community’s Attention on Peptides

Serious adverse events are reportable regardless of whether they are considered drug-related. The labeling must explain how to report adverse events and concerns involving product identity, strength, purity, or quality, while also including the following statement: “This is a compounded drug product. Not for resale.” Pharmacies should establish procedures for receiving complaints from prescribers and platforms, investigating affected lots, and completing reports; the document does not specify every reporting deadline or submission detail.

What Providers Should Address

The policy preserves the patient-specific prescription requirement and all other applicable FD&C Act requirements, including the prohibition against insanitary compounding conditions. It would not establish a general office-stock or resale pathway for clinics. Pharmacy operations would still require attention to applicable compounding standards, state licensure, and interstate dispensing restrictions. Stakeholders should not assume that state licensing boards will adopt the same enforcement approach.

For prescribers, federal enforcement discretion does not resolve whether a particular peptide is appropriate for a particular patient. Providers should document their clinical rationale, discuss the preparation's unapproved status and relevant uncertainties, consider alternatives, and arrange follow-up. Consent forms cannot substitute for an adequate evaluation or appropriate clinical judgment.

Marketing requires equally careful review. The policy would not substantiate claims that peptides reverse aging, accelerate recovery, or treat particular diseases, and patient testimonials do not eliminate the need for appropriate scientific support. Websites and intake materials should accurately describe compounded products and avoid suggesting that HHS enforcement discretion amounts to FDA endorsement.

Preparing a Defensible Peptide Compounding Program

Before launching or expanding services, stakeholders should assess each proposed product against the policy's actual conditions. That review should connect the precise API and route with supplier qualification, testing documentation, prescription practices, labeling, and reporting procedures. Contracts should also address interruptions if a supplier fails qualification or HHS changes its position.

Insurance and reimbursement deserve separate attention because this policy would not establish payer coverage or malpractice protection. Pharmacies, providers, and telemedicine companies should review applicable agreements and exclusions before making commitments to patients. A federal enforcement policy cannot resolve those contractual questions.

The HHS document presents a meaningful potential opening for regulated peptide compounding, with substantial responsibilities attached. Pharmacies and their clinical partners should use this period to evaluate whether they can meet those responsibilities consistently and document that work. Confirming the operative policy and resolving product-specific questions before dispensing will be essential to protecting patients and the business.

READ MORE: Pharmacy Law Lowdown Resource Center

REFERENCES

1. HHS enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. US Department of Health and Human Services. October 28, 2026. Accessed October 28, 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf

2. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. US Department of Health and Human Services. October 28, 2026. Accessed October 28, 2026. https://www.federalregister.gov/d/2026-22192